Needham analyst Michael Matson reiterated a Buy rating on Merit Medical Systems (MMSI – Research ... This suggests robust demand for its products and effective execution of its business strategy.

and Cook Medical LLC and its ability to achieve anticipated financial results, product development and other anticipated benefits of those acquisitions; disruptions in Merit’s supply chain ...

Additionally, the anticipation surrounding Merit Medical’s upcoming investor day, where the potential of the recently FDA-approved Wrapsody product will be discussed, contributes to the positive ...

Merit Medical Systems (NASDAQ ... Merit plans to begin commercializing the product in the U.S. in 2025. In a note, Needham analyst Mike Matson said the approval came earlier than expected.

Merit Medical Systems, Inc. (NASDAQ:MMSI) designs, develops, manufactures, and markets single-use medical products. The one-month return of Merit Medical Systems, Inc. (NASDAQ:MMSI) was -7.95% ...

Merit Medical Systems, Inc. MMSI announced preliminary revenues for 2024 on Monday. Following the robust preliminary results, the company’s shares gained nearly 3.9% till yesterday’s closing.

The FDA approval of the WRAPSODY Cell-Impermeable Endoprosthesis is a significant milestone for Merit Medical as it enables the company to expand its product portfolio into the vascular ...

About Merit Medical Systems, Inc., LeMaitre Vascular and Inc. Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and ...